Standard of Care Durvalumab for Limited-Stage SCLC

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Anne Chiang, MD, PhD

Key Takeaways

Durvalumab demonstrated promising results in limited-stage SCLC in the ADRIATIC trial, potentially improving patient outcomes.
The ADRIATIC trial's design evaluated durvalumab's efficacy, suggesting its integration into treatment algorithms if approved.
Unmet needs addressed by the ADRIATIC trial include enhancing survival rates and offering new therapeutic options for limited-stage SCLC patients.

Panelists discuss how the ADRIATIC trial investigating durvalumab in limited-stage small cell lung cancer (SCLC) has shown promising results, potentially addressing unmet needs in this patient population, and consider its potential impact on treatment algorithms and its possible emergence as a new standard of care if approved for this indication.

EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC

EP: 2.Established Multidisciplinary Therapies for SCLC

EP: 3.Immunotherapies for Extensive-Stage SCLC

EP: 4.Introducing Bispecifics for Extensive-Stage SCLC

Now Viewing

EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC

EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC

EP: 7.Payer and Patient Education Considerations for SCLC

EP: 8.Biomarker Discovery and Exploration for SCLC

EP: 9.Key Takeaways on Recent Advances in SCLC

EP: 10.Therapies Beyond the Front Line for SCLC

EP: 11.Timing and Urgency Considerations in SCLC

Now that we’ve discussed extensive-stage small cell lung cancer (SCLC), let’s move into limited stage. Durvalumab has also demonstrated encouraging results in patients with limited-stage SCLC in the ADRIATIC trial. Can you discuss the trial design and the key results that were seen?

How do you see durvalumab fitting into treatment algorithms if approved? Do you see it as a potential new standard of care for patients with limited-stage SCLC?

What are the unmet needs that the ADRIATIC trial addresses for patients with limited-stage SCLC?